#United States #New York #Faruqi & Faruqi #AQST #Aquestive

Urgent Notice for Investors in Aquestive Therapeutics

As the May 4, 2026 deadline approaches, investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST) are reminded by the renowned securities law firm Faruqi & Faruqi, LLP of their legal rights regarding potential claims against the company. This follows a significant downturn for Aquestive's stock that saw a sharp decline on January 9, 2026, following concerning developments regarding their New Drug Application (NDA) for Anaphylm.

Background of the Case

The lawsuit revolves around allegations that Aquestive Therapeutics and its executives violated federal securities laws, misleading investors by not fully disclosing crucial information about the company’s FDA NDA for Anaphylm. Reports indicated that deficiencies were found in the NDA, which hindered discussions related to subsequent commitments following the marketing approval of the drug. This lack of transparency led to a dramatic fall in the company’s stock price, falling 37.04% to close at $3.91 per share after the announcement.

Faruqi & Faruqi has extensive experience in handling cases of this nature and has secured millions in recoveries for investors in past litigation. With offices in major cities including New York and California, the firm has established itself as a trusted advisor for individuals who have suffered financial losses.

Call for Investors to Take Action

James (Josh) Wilson, a Senior Partner at Faruqi & Faruqi, is particularly encouraging investors who acquired Aquestive securities between June 16, 2025, and January 8, 2026, to reach out directly to discuss their legal rights. This outreach not only assists affected investors in understanding their options but also aims to organize a collective approach to the lawsuit where a lead plaintiff can be designated.

Investor participation is crucial; it empowers individuals affected by corporate misdirection to unite under one representation. The firm continues to highlight the importance of this collective action and encourages anyone with pertinent information related to Aquestive’s conduct—including former employees and whistleblowers—to come forward.

What Investors Should Do

Investors looking to play an active role can either submit their intentions to be considered for the lead plaintiff position or continue as passive class members; either choice does not impact the potential recovery from the litigation. Those interested in learning more about the class action—its implications and potential outcomes—are encouraged to visit the Faruqi & Faruqi website or contact the firm directly. The process has also been facilitated via digital platforms, making it easier for individuals to stay updated.

The upcoming May 4 deadline serves as a pivotal moment for investors, as it determines the eligibility to participate actively in the ongoing litigation process. All communications with Faruqi & Faruqi will be treated confidentially, ensuring that sensitive information is protected.

Conclusion

Overall, this climax in the events around Aquestive Therapeutics underscores the essential role of investor awareness and proactive legal support in the landscape of corporate law. As the clock ticks down to the May 4 deadline, investors are advised to assess their positions critically and consider whether they wish to engage with the legal proceedings that could potentially lead to restitution for their incurred losses.